ResMed Inc. vs Sezzle Inc — how do they compare? ResMed Inc. trades at $225.19 (market cap $32.61B), while Sezzle Inc trades at $126.1 (market cap $4.32B). The key difference: ResMed Inc. is far larger — about 7.5× Sezzle Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals.
| RMD | SEZL | |
|---|---|---|
Market Cap | $32.61B | $4.32B |
Sector | Health | Technology |
52-Week High | $293.73 | $188.55 |
52-Week Low | $182.82 | $50.97 |
Enterprise Value | $31.97B | $4.36B |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Sezzle (SEZL) trades at $125.44, up 6.31% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 30.35% net income margin and consistent earnings beats. Recent Q2 2026 results showed revenue growth of 51.7% year-over-year to $149.7 million, with management raising full-year guidance for the third time in 2026, indicating robust operational momentum despite a recent stock decline.
The outlook is mixed: bullish fundamentals and analyst consensus support upside to a $158.29 price target, but technical indicators and valuation premiums pose risks. Key opportunities include subscriber growth and AI integration, while risks involve execution pressure and market volatility. Investors should weigh strong profitability against high P/E and P/S ratios.
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →